Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients

American Journal of Nephrology

Volumn 24, Issue 6, 2004, Pages 624-629

  Małyszko, Jolanta ^a   Małyszko, Jacek S ^a   Hryszko, Tomasz ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Dalteparin; Enoxaparin; Hemodialysis; Hemostasis; TAFI; Unfractionated heparin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIPLASMIN; BIOLOGICAL MARKER; DALTEPARIN; ENOXAPARIN; HEPARIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CATALYST; CHRONIC GLOMERULONEPHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG SAFETY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; EVALUATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOSTASIS; HUMAN; INFUSION PUMP; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; CARBOXYPEPTIDASE U; DALTEPARIN; ENOXAPARIN; FEMALE; HEMOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMIN; PROTEIN PRECURSORS; PROTHROMBIN; RENAL DIALYSIS; THROMBOMODULIN; THROMBOSIS;

EID: 13244273798     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082862     Document Type: Article

References (19)

1. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
2. Bajzar L: Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;11:2511-2516.
3. Colucci M, Pentimone A, Binetti BM, Cramarossa M, Piro D, Semeraro N: Effect of heparin on TAFI-dependent inhibition of fibrinolysis: Relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost 2002;88:282-287.
4. Lisman T, de Groot PG: Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. J Thromb Haemost 2003;1:200-201.
5. Kakkar VV, Hoppenstead DA, Fareed J, et al: Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002;99:1965-1970.
6. Saltissi D, Morgan C, Westhuyzen J, Healy H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for hemodialysis anticoagulation. Nephrol Dial Transplant 1999;14:2698-2703.
7. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Brosstad F: Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001;16:987-993.
8. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999;14:1943-1947.
9. van Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-2859.
10. Hryszko T, Małyszko J, Małyszko JS, Brzósko S, Pawlak K, Myśliwiec M: A possible role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 2001;16:1692-1696.
11. Hryszko T, Małyszko J, Małyszko JS, Brzósko S, Myśliwiec M: Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis activity. Thromb Res 2001;104:233-238.
12. Naumnik B, Borawski J, Myśliwiec M: Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: A prospective study. Nephrol Dial Transplant 2003;18:1376-1382.
13. Stefoni S, Cianciolo G, Donati G, et al: Standard heparin versus low-molecular-weight heparin: A medium-term comparison in hemodialysis. Nephron 2002;92:589-600.
14. Boffa MB, Hamill JD, Maret D, et al: Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003;278:9250-9257.
15. Koschinsky ML, Boffa MB, Nesheim ME, et al: Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activatable fibrinolysis inhibitor (TAF1) with blood pressure. Clin Genet 2001;60:345-349.
16. Nagashima M, Yin ZF, Zhao L, et al: Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002;109:101-110.
17. Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich JE: Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol Dial Transplant 2002;17:2231-2238.
18. Puccetti L, Pasqui AL, Pastorelli M, et al: Different mechanisms of fibrinolysis impairment among dyslipidemic subjects. Int J Clin Pharmacol Res 2001;21:147-155.
19. Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M: Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia. Transplant Proc 2003;35:2219-2221.